Mohammed Haneefa Nizamudeen/iStock via Getty Images
- Cellular therapeutics company BioCardia (NASDAQ:BCDA) said on Thursday that the Food and Drug Administration has cleared the company to market its Morph DNA Steerable Introducer product family.
- The clearance covers sixteen products in lengths of 30, 45, 71, and 90 centimeters in 5, 6, 7, and 8 French introducer sheath equivalent diameters.
- These products are expected to cover clinical applications in interventional cardiology, radiology, and vascular surgery.
- “We estimate that more than a million procedures performed per year in the United States may benefit from these products, which are expected to have a list price starting at $1,000,” Peter Altman, BioCardia (BCDA) CEO said.
- BioCardia (BCDA) shares were up 96.8% in pre-market trading on Thursday.
